NADA (N-Arachidonyldopamine), endogenous CB1 / TRPV1 agonist (ab120099)

Submit a review Submit a question References (1)

Overview

  • Product name

    NADA (N-Arachidonyldopamine), endogenous CB1 / TRPV1 agonist

  • Description

    Endogenous CB1 / TRPV1 agonist

  • Alternative names

    • N-Arachidonyldopamine

  • Biological description

    Potent endogenous cannabinoid and vanilloid receptor agonist. (Ki values are 0.25 and 12 μM for CB1 and CB2, respectively). Potent agonist at TRPV1 (VR1) receptors (EC50 = ~50 nM). Active in vivo.

  • Purity

    > 98%

  • CAS Number

    199875-69-9

  • Chemical structure

    Chemical Structure

Properties

Applications

Our Abpromise guarantee covers the use of ab120099 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Functional Studies Use at an assay dependent concentration.

Images

  • Functional Studies - NADA (N-Arachidonyldopamine), endogenous CB<sub>1</sub> / TRPV1 agonist (ab120099)
    Functional Studies - NADA (N-Arachidonyldopamine), endogenous CB1 / TRPV1 agonist (ab120099)
    ab15580 staining Ki67 in SK-N-SH cells treated with NADA (N-Arachidonyldopamine) (ab120099), by ICC/IF. Decrease in Ki67 expression correlates with increased concentration of NADA (N-Arachidonyldopamine), as described in literature.
    The cells were incubated at 37°C for 10 minutes in media containing different concentrations of ab120099 (NADA (N-Arachidonyldopamine)) in ethanol, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab15580 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

Protocols

To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

Click here to view the general protocols

References

Publishing research using ab120099? Please let us know so that we can cite the reference in this datasheet.

ab120099 has been referenced in 1 publication.

  • Ferreira SG  et al. N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. Neuropharmacology 56:676-83 (2009). PubMed: 19101577

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

There are currently no Customer reviews or Questions for ab120099.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com